Armed with AstraZeneca deal, Eccogene files for Hong Kong IPO
The Chinese biotech is developing a weight-loss drug in a tablet form that could challenge leading products in the booming anti-obesity market Key Takeaways: The AstraZeneca licensing deal in 2023…
Hengrui Pharma targets obesity drug launch after test success
The Chinese drug company is looking to break into the big league for weight-loss treatments after its injection demonstrated sustained weight loss in Phase Three trials Key Takeaways: Participants receiving…
AstraZeneca pays hefty price for Chinese weight-loss drug
The drugs giant has licensed an experimental anti-obesity pill from China’s Eccogene as it tries to grab a chunk of the lucrative weight-loss market Key Takeaways: Chinese biotech Eccogene says…
RELATED ARTICLES
-
Hengrui Pharma targets obesity drug launch after test success
1278.HK 600276.SHG
- Obesity drug maker Sciwind targets IPO, with heavyweight backers
-
HBM notches up another mega deal but is the model sustainable?
2142.HK
-
Medtide launches IPO to bulk up its weight-loss business
3880.HK
-
3SBio hits the big time with $6 billion cancer drug deal
1530.HK
-
InnoCare licensing deal flops due to lack of upfront cash
9969.HK 688428.SHG
-
Kintor Pharma shifts from cancer drugs to cosmetics as funds run low
9939.HK
